Research
Hormonal
Retatrutide, a triple GLP-1/GCGR/GIP receptor agonist, produces significant weight loss (-22.1% placebo-subtracted) in individuals with obesity.
Retatrutide is an emerging triple-agonist injection that targets GLP-1, GCGR, and GIP receptors to produce significant weight loss. It is currently in phase II trials, so long-term safety data is not yet fully established, but early results show high efficacy.
ModerateSupportsMEDIUM confidence
Retatrutide, a GLP1R/GCGR/GIPR tri‑agonist, has been associated with a placebo‑subtracted weight reduction of ‑22.1% in a 48‑week phase‑II trial.
Why this rating
Based on a phase II trial, which is earlier stage than phase III.
Source
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Wael R. Sidrak et al. · Indian Journal of Endocrinology and Metabolism · 2024
DOI 10.4103/ijem.ijem_442_23
narrative_reviewCited 15×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →